🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Solid Tumor, Adult

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors NCT05866692Phase 12 sites📍 Beijing📍 Jinan TYK Medicines, Inc · Tests: TY-2699a A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement NCT07359820Phase 219 sites📍 Phoenix📍 Jacksonville📍 Tampa Elevar Therapeutics · Tests: Lirafugratinib A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors NCT05584670Phase 1, Phase 222 sites📍 Newark📍 Iowa City📍 Westwood Sanofi · Tests: SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors NCT07174661NA1 site📍 Scottsdale Mayo Clinic · Tests: Advance Care Planning, Educational Intervention, Electronic Health Record Review, Survey Administration Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors NCT06532565Phase 16 sites📍 Palo Alto📍 Boston📍 San Antonio Gilead Sciences · Tests: GS-2121, Zimberelimab Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site📍 Jinan Mainline Biosciences (Shanghai) Co., Ltd · Tests: MB0151 for injection A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840Phase 148 sites📍 Phoenix📍 Scottsdale📍 Duarte Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) A Study of LY4337713 in Participants With FAP-Positive Solid Tumors NCT07213791Phase 130 sites📍 Newport Beach📍 Stanford📍 Miami Eli Lilly and Company · Tests: LY4337713 Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 ORB-021 In Patients With Advanced Solid Tumors NCT06607939Phase 12 sites📍 Scottsdale📍 Houston Orionis Biosciences Inc · Tests: ORB-021 BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558Phase 115 sites📍 New Haven📍 Plainville📍 Gainesville Astellas Pharma Global Development, Inc. · Tests: ASP1002, Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326Phase 1, Phase 214 sites📍 Dothan📍 Scottsdale📍 Beverly Hills Krystal Biotech, Inc. · Tests: KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585Phase 1, Phase 241 sites📍 Scottsdale📍 Fullerton📍 Los Angeles Alentis Therapeutics AG · Tests: ALE.P02, Pembrolizumab A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors NCT07228247Phase 1, Phase 215 sites📍 Denver📍 Plantation📍 Plantation Hutchmed · Tests: HMPL-A251, HMPL-A251 Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors NCT06088004Phase 1, Phase 25 sites📍 Beijing📍 Guangzhou📍 Nanning Suzhou Abogen Biosciences Co., Ltd. · Tests: ABO2011 Injection, Toripalimab CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors NCT07335497Phase 1, Phase 234 sites📍 Birmingham📍 Los Angeles📍 Denver Crescent Biopharma, Inc. · Tests: CR-001, Paclitaxel, trifluridine and tipiracil, Pemetrexed, Carboplatin Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors NCT04803318Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies NCT04412616Phase 15 sites📍 Los Angeles📍 Fairway📍 The Bronx Changchun Intellicrown Pharmaceutical Co. LTD · Tests: ZZ06 Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors NCT05868174Phase 15 sites📍 North Ryde📍 Adelaide📍 Brisbane Telix Pharmaceuticals (Innovations) Pty Limited · Tests: 89Zr-TLX250, 177Lu-TLX250 and Peposertib Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors NCT06132503Phase 11 site📍 West Valley City Lantern Pharma Inc. · Tests: LP-284 AIMS Cancer Outcomes Study NCT04495790n/a1 site📍 Seattle Advanced Integrative Medical Science Institute JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors NCT06108050Phase 110 sites📍 Encinitas📍 Fresno📍 Denver Jazz Pharmaceuticals · Tests: JZP898, Pembrolizumab A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites📍 Los Angeles📍 Denver📍 New Haven GV20 Therapeutics · Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor NCT06883149Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: PIN +anti-PD1 GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites📍 Goyang-si📍 Seoul📍 Seoul GeneMedicine Co., Ltd. · Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors NCT04842812Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer NCT05947695NA1 site📍 West Islip Good Samaritan Hospital Medical Center, New York · Tests: Palliative and Survivorship Care Model Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors NCT04643418Phase 1, Phase 21 site📍 Taipei MegaPro Biomedical Co. Ltd. · Tests: MPB-1734
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy